NCT06147063View on ClinicalTrials.gov

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

March 27, 2025

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

AZD9838

Intramuscular (IM) injection.

BIOLOGICAL

Licensed mRNA vaccine

Intramuscular (IM) injection.

BIOLOGICAL

AZD6563

Intramuscular (IM) injection.

Trial Locations (5)

29405

Research Site, North Charleston

60640

Research Site, Chicago

67207

Research Site, Wichita

90274

Research Site, Rolling Hills Estates

90815

Research Site, Long Beach

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY